MedPageToday -- SAN ANTONIO -- A combination of trastuzumab (Herceptin) and prophylactic cranial radiation to prevent brain metastases did not appear to cause cognitive dysfunction among metastatic breast cancer patients, compared with those given the drug without radiation, according to a small clinical trial reported here.
